{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:21:15Z","timestamp":1794932475570,"version":"4.9.1"},"reference-count":95,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Activation of the type 1 interferon (T1 IFN) pathway has been implicated in the pathogenesis of systemic sclerosis (SSc) by an increasing number of studies, most of which share key findings with similar studies in systemic lupus erythematosus (SLE). Here we will focus on the evidence for T1 IFN activation and dysregulation in SSc, and the rationale behind targeting the pathway going forward.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>An increased expression and activation of T1 IFN-regulated genes has been shown to be present in a significant proportion of SSc patients. TI IFN activation markers have been found to predict and correlate with response to immunosuppressive treatment as well as severity of organ involvement. As inhibition of the IFN-\u03b1 receptor has been proven to be effective in active SLE, benefit may be seen in targeting the IFN pathway in SSc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The role played by T1 IFN and its regulatory genes in SSc is becoming increasingly evident and strikingly similar to the role observed in SLE. This observation, together with the benefit of type 1 IFN targeting in SLE, supports the notion of a potential therapeutic benefit in targeting T1 IFN in SSc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000907","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T12:23:11Z","timestamp":1663676591000},"page":"357-364","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":61,"title":["Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit"],"prefix":"10.1097","volume":"34","author":[{"given":"Vishal","family":"Kakkar","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Texas Health Science Center at Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[{"name":"INSERM U1016 UMR 8104, Universit\u00e9 Paris Cit\u00e9, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[{"name":"Royal Free Hospital, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250526","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","author":"Lescoat","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40674-021-00188-9","article-title":"Dysregulation of type 1 interferon signaling in systemic sclerosis: a promising therapeutic target?","volume":"7","author":"Wu","year":"2021","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"154635","DOI":"10.1016\/j.cyto.2018.12.018","article-title":"Type I interferon dysregulation in systemic sclerosis","volume":"132","author":"Skaug","year":"2020","journal-title":"Cytokine"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"e000625","DOI":"10.1136\/lupus-2021-000625","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Med"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"608645","DOI":"10.3389\/fimmu.2020.608645","article-title":"Importance of type I and III interferons at respiratory and intestinal barrier surfaces","volume":"11","author":"Stanifer","year":"2020","journal-title":"Front Immunol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3389\/fimmu.2018.02379","article-title":"Pattern recognition receptors and the host cell death molecular machinery","volume":"9","author":"Amarante-Mendes","year":"2018","journal-title":"Front Immunol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cei.13426","article-title":"Toll-like receptors in mediating pathogenesis in systemic sclerosis","volume":"201","author":"Frasca","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fmed.2020.00352","article-title":"When innate immunity meets angiogenesis-the role of toll-like receptors in endothelial cells and pulmonary hypertension","volume":"7","author":"Bhagwani","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20132620","article-title":"Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model","volume":"211","author":"Rowland","year":"2014","journal-title":"J Exp Med"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2020-218439","article-title":"Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma","volume":"80","author":"Ross","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"eaam8458","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Sci Transl Med"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s41467-019-09683-z","article-title":"CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-\u03b1 production in systemic sclerosis","volume":"10","author":"Lande","year":"2019","journal-title":"Nat Commun"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.3390\/ijms21145102","article-title":"Anti-CXCL4 antibody reactivity is present in systemic sclerosis (SSc) and correlates with the SSc type i interferon signature","volume":"21","author":"Lande","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib10020012","article-title":"New autoantibody specificities in systemic sclerosis and very early systemic sclerosis","volume":"10","author":"Lande","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1465-9921-10-43","article-title":"Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice","volume":"10","author":"Stowell","year":"2009","journal-title":"Respir Res"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"15136","DOI":"10.1073\/pnas.1520997112","article-title":"Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis","volume":"112","author":"Saigusa","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-20250526","first-page":"539282","article-title":"Autoimmunity in rheumatic diseases is induced by microbial infections via crossreactivity or molecular mimicry","volume":"2012","author":"Rashid","year":"2012","journal-title":"Autoimmune Dis"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2008.07.022","article-title":"Systemic sclerosis and infections","volume":"8","author":"Randone","year":"2008","journal-title":"Autoimmun Rev"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-017-1237-9","article-title":"Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes","volume":"19","author":"Farina","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/jid.2013.423","article-title":"Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma","volume":"134","author":"Farina","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"651013","DOI":"10.3389\/fimmu.2021.651013","article-title":"Innate immune modulation induced by EBV lytic infection promotes endothelial cell inflammation and vascular injury in scleroderma","volume":"12","author":"Farina","year":"2021","journal-title":"Front Immunol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/art.41418","article-title":"Bioactive plasma mitochondrial DNA is associated with disease progression in scleroderma-associated interstitial lung disease","volume":"72","author":"Ryu","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1126\/science.aaz9308","article-title":"Mitochondrial DNA promotes autoimmunity","volume":"366","author":"Crow","year":"2019","journal-title":"Science"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nri.2017.21","article-title":"Mitochondrial DNA in innate immune responses and inflammatory pathology","volume":"17","author":"West","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S","article-title":"Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts","volume":"44","author":"Arnett","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaut.2010.02.001","article-title":"Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis","volume":"35","author":"Arora-Singh","year":"2010","journal-title":"J Autoimmun"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00438-021-01805-x","article-title":"Classifying single nucleotide polymorphisms in humans","volume":"296","author":"Azizzadeh-Roodpish","year":"2021","journal-title":"Mol Genet Genomics"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways","volume":"10","author":"L\u00f3pez-Isac","year":"2019","journal-title":"Nat Commun"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.39730","article-title":"Brief Report: IRF4 newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies","volume":"68","author":"L\u00f3pez-Isac","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/art.24183","article-title":"Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis","volume":"60","author":"Dieud\u00e9","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ng.565","article-title":"Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus","volume":"42","author":"Radstake","year":"2010","journal-title":"Nat Genet"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/annrheumdis-2011-200275","article-title":"Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis","volume":"71","author":"Carmona","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"e1002178","DOI":"10.1371\/journal.pgen.1002178","article-title":"Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy","volume":"7","author":"Gorlova","year":"2011","journal-title":"PLoS Genet"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-015-0572-y","article-title":"Identification of NF-\u03baB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis","volume":"17","author":"Arismendi","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ng1782","article-title":"A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus","volume":"38","author":"Graham","year":"2006","journal-title":"Nat Genet"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.23426","article-title":"Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis","volume":"58","author":"Dieguez-Gonzalez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/art.30193","article-title":"Association of a functional IRF7 variant with systemic lupus erythematosus","volume":"63","author":"Fu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"e1002341","DOI":"10.1371\/journal.pgen.1002341","article-title":"Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus","volume":"7","author":"Cunninghame Graham","year":"2011","journal-title":"PLoS Genet"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/annrheumdis-2015-208154","article-title":"Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway","volume":"75","author":"L\u00f3pez-Isac","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/BOR.0000000000000735","article-title":"Systemic sclerosis pathogenesis: contribution of recent advances in genetics","volume":"32","author":"Orvain","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"102727","DOI":"10.1016\/j.jaut.2021.102727","article-title":"Insights into the knowledge of complex diseases: environmental infectious\/toxic agents as potential etiopathogenetic factors of systemic sclerosis","volume":"124","author":"Ferri","year":"2021","journal-title":"J Autoimmun"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jid.2017.12.003","article-title":"Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of IFN-associated genes in CD4(+) and CD8(+) T cells","volume":"138","author":"Ding","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/annrheumdis-2012-203194","article-title":"The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis","volume":"73","author":"Dees","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/annrheumdis-2014-205303","article-title":"Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies","volume":"74","author":"Altorok","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/annrheumdis-2012-201615","article-title":"Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis","volume":"72","author":"Kr\u00e4mer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2018-214295","article-title":"Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting","volume":"78","author":"Van der Kroef","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"102396","DOI":"10.1016\/j.autrev.2019.102396","article-title":"Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy","volume":"18","author":"Henry","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1759720x20918456","DOI":"10.1177\/1759720X20918456","article-title":"The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview","volume":"12","author":"Fioretto","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"(Suppl 3)","key":"R55-20250526","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.5152\/eurjrheum.2020.19112","article-title":"Epigenetics and systemic sclerosis: an answer to disease onset and evolution?","volume":"7","author":"Ramahi","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-020-02376-9","article-title":"Long noncoding RNA HOTAIR induces GLI2 expression through Notch signalling in systemic sclerosis dermal fibroblasts","volume":"22","author":"Wasson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.40163","article-title":"Association of microRNA-618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis","volume":"69","author":"Rossato","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13148-019-0632-2","article-title":"The emerging role of epigenetics in human autoimmune disorders","volume":"11","author":"Mazzone","year":"2019","journal-title":"Clin Epigenet"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fimmu.2019.00100","article-title":"The long noncoding RNA NRIR Drives IFN-response in monocytes: implication for systemic sclerosis","volume":"10","author":"Mariotti","year":"2019","journal-title":"Front Immunol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","article-title":"Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients","volume":"45","author":"Tan","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2017.10.011","article-title":"Targeting interferons as a strategy for systemic sclerosis treatment","volume":"195","author":"Ciechomska","year":"2018","journal-title":"Immunol Lett"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"275617","DOI":"10.1155\/2011\/275617","article-title":"Basal activation of type i interferons (Alpha2 and Beta) and 2\u20195\u2019OAS genes: insights into differential expression profiles of interferon system components in systemic sclerosis","volume":"2011","author":"de Oliveira","year":"2011","journal-title":"Int J Rheumatol"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/ITT.S82037","article-title":"Current perspectives on the immunopathogenesis of systemic sclerosis","volume":"5","author":"Fuschiotti","year":"2016","journal-title":"Immunotargets Ther"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","article-title":"Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCRESAHA.114.302221","article-title":"Evidence for the involvement of type I interferon in pulmonary arterial hypertension","volume":"114","author":"George","year":"2014","journal-title":"Circ Res"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis\u2013related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","article-title":"A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"62","author":"Farina","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-021-02633-5","article-title":"Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?","volume":"23","author":"Farutin","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2021-221313","article-title":"Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease","volume":"81","author":"Assassi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/jid.2015.188","article-title":"Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis","volume":"135","author":"Guo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4049\/jimmunol.1502190","article-title":"Type I IFNs regulate inflammation, vasculopathy, and fibrosis in chronic cutaneous graft-versus-host disease","volume":"197","author":"Delaney","year":"2016","journal-title":"J Immunol"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/annrheumdis-2019-215770","article-title":"Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures","volume":"78","author":"Assassi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.41627","article-title":"Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis-related interstitial lung disease","volume":"73","author":"Assassi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3899\/jrheum.080418","article-title":"Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis","volume":"35","author":"Air\u00f2","year":"2008","journal-title":"J Rheumatol"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jcp.24337","article-title":"Interferon-\u03b3 promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) \u03b22","volume":"228","author":"Chrobak","year":"2013","journal-title":"J Cell Physiol"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2353\/ajpath.2010.090593","article-title":"Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy","volume":"176","author":"Asano","year":"2010","journal-title":"Am J Pathol"},{"key":"R81-20250526","first-page":"2021","article-title":"ABSTRACT NUMBER: 1856 - aerum IFN score predicts long term outcome in limited cutaneous SSc","volume":"2021","author":"Karanth","year":"2021","journal-title":"ACR Convergence"},{"key":"R82-20250526","doi-asserted-by":"crossref","first-page":"14433","DOI":"10.1038\/s41598-019-50231-y","article-title":"SLE plasma profiling identifies unique signatures of lupus nephritis and discoid lupus","volume":"9","author":"Smith","year":"2019","journal-title":"Sci Rep"},{"key":"R83-20250526","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R84-20250526","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1038\/s41598-020-60563-9","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"R85-20250526","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sj\u00f6gren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R86-20250526","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R87-20250526","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.30187","article-title":"Network analysis of associations between serum interferon-\u03b1 activity, autoantibodies, and clinical features in systemic lupus erythematosus","volume":"63","author":"Weckerle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R88-20250526","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R89-20250526","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R90-20250526","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R91-20250526","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","article-title":"Expression of long interspersed nuclear element 1 retroelements and induction of type i interferon in patients with systemic autoimmune disease","volume":"68","author":"Mavragani","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R92-20250526","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R93-20250526","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun"},{"key":"R94-20250526","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2019","journal-title":"New Engl J Med"},{"key":"R95-20250526","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human antiinterferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:19:15Z","timestamp":1748279955000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000907","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}